Document Detail


Dapoxetine: a new option in the medical management of premature ejaculation.
MedLine Citation:
PMID:  23024705     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Premature ejaculation (PE) is a common male sexual disorder which is associated with substantial personal and interpersonal negative psychological consequences. Pharmacotherapy of PE with off-label antidepressant selective serotonin reuptake inhibitors (SSRIs) is common, effective and safe. Development and regulatory approval of drugs specifically for the treatment of PE will reduce reliance on off-label treatments and serve to fill an unmet treatment need. The objective of this article is to review evidence supporting the efficacy and safety of dapoxetine in the treatment of PE. MEDLINE, Web of Science, PICA, EMBASE and the proceedings of major international and regional scientific meetings were searched for publications or abstracts published during the period 1993-2012 that used the word 'dapoxetine' in the title, abstract or keywords. This search was then manually cross referenced for all papers. This review encompasses studies of dapoxetine pharmacokinetics, animal studies, human phase I, II and III studies, independent postmarketing and pharmacovigilance efficacy and safety studies and drug-interaction studies. Dapoxetine is a potent SSRI which is administered on demand 1-3 h prior to planned sexual contact. It is rapidly absorbed and eliminated, resulting in minimal accumulation, and has dose-proportional pharmacokinetics which are unaffected by multiple dosing. Dapoxetine 30 mg and 60 mg has been evaluated in five industry-sponsored randomized, double-blind, placebo-controlled studies in 6081 men aged at least 18 years. Outcome measures included stopwatch-measured intravaginal ejaculatory latency time (IELT), Premature Ejaculation Profile (PEP) inventory items, Clinical Global Impression of Change (CGIC) in PE, and adverse events. Mean IELT, all PEP items and CGIC improved significantly with both doses of dapoxetine versus placebo (all p <0.001). The most common treatment-related adverse effects included nausea (11.0% for 30 mg, 22.2% for 60 mg), dizziness (5.9% for 30 mg, 10.9% for 60 mg), and headache (5.6% for 30 mg, 8.8% for 60 mg), and evaluation of validated rated scales demonstrated no SSRI class-related effects with dapoxetine use. Dapoxetine, as the first drug developed for PE, is an effective and safe treatment for PE and represents a major advance in sexual medicine.
Authors:
Chris G McMahon
Related Documents :
10331415 - Metabolic and hemodynamic effects of moxonidine in the zucker diabetic fatty rat model ...
16903985 - A randomized, open-label study to compare the effects of two different doses of recombi...
1235055 - The carcinogenic effect of dimethylnitrosamine on the chinese hamster (cricetulus grise...
8006295 - Dietary and serum magnesium levels in patients with acute myocardial infarction, corona...
9408195 - Effects of physostigmine on the startle in guinea pigs: two mechanisms involved.
7438695 - Hydralazine kinetics after single and repeated oral doses.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Therapeutic advances in urology     Volume:  4     ISSN:  1756-2880     ISO Abbreviation:  Ther Adv Urol     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-01     Completed Date:  2012-10-02     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101487328     Medline TA:  Ther Adv Urol     Country:  England    
Other Details:
Languages:  eng     Pagination:  233-51     Citation Subset:  -    
Affiliation:
Australian Centre for Sexual Health, Suite 2-4, 1a Berry Rd, St Leonards, New South Wales 2065, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current approaches to bone-targeted therapy in genitourinary malignancies.
Next Document:  Experience with sunitinib in the treatment of metastatic renal cell carcinoma.